EUVIMEDEUVIMED entdecken
Crossref

The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism

O A Buneeva, I G Kapitsa, M G Zavyalova, S A Kaloshina, V G Zgoda, A E Medvedev

Biomeditsinskaya Khimiya · 2025

DOI: 10.18097/pbmcr1586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomeditsinskaya Khimiya, 2025. Verfasst von O A Buneeva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Chemistry, Moscow, Russia. Hauptthemen laut MEDLINE: Proteome, Brain, Neuroprotective Agents, Parkinsonian Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabomotizole is an original anxiolytic agent developed at the Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies that acts on a number of important receptor systems of the brain. In a model of Parkinson's disease induced in rats by a course of rotenone administration, fabomotizole attenuated manifestations of behavioral impairments and influenced the profile and relative content of brain proteins. Five days after the last administration of rotenone, the fabomotizole effect on the behavioral reactions of rats persisted. According to the proteomic study, the profile of brain proteins and changes in their relative content differed significantly from the results obtained immediately after the last administration of rotenone, as well as rotenone in combination with fabomotizole. Changes in the relative content of almost all proteins detected immediately after the last administration of rotenone or rotenone with fabomotizole were not detectable five days later. However, at this time point, there were changes in the relative content of other proteins associated with neurodegeneration in Parkinson's and Alzheimer's diseases. Such dynamics suggests a wave-like change in the content of pathogenetically important brain proteins involved in the mechanisms of neurodegeneration and neuroprotection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomeBrainNeuroprotective AgentsParkinsonian DisordersNerve Tissue ProteinsParkinson Disease, SecondaryAnimalsRotenoneRatsMaleDisease Models, AnimalRats, WistarBenzimidazolesMorpholines

Stichwörter der Autor:innen

brain proteinsfabomotizoleneurodegenerationneuroprotectorproteomic profilingrotenone

Substanzen

RotenoneProteomeNeuroprotective Agents2-((2-morpholino)ethylthio)-5-ethoxybenzimidazoleNerve Tissue ProteinsBenzimidazolesMorpholines

Autor:innen und Institutionen

  • Institute of Biomedical Chemistry, Moscow, Russia.
  • Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

Zitieren

APA

Buneeva, O. A., Kapitsa, I. G., Zavyalova, M. G., Kaloshina, S. A., Zgoda, V. G., & Medvedev, A. E. (2025). The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism. Biomeditsinskaya Khimiya. https://doi.org/10.18097/pbmcr1586

Vancouver

Buneeva OA, Kapitsa IG, Zavyalova MG, Kaloshina SA, Zgoda VG, Medvedev AE. The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism. Biomeditsinskaya Khimiya. 2025. doi:10.18097/pbmcr1586

BibTeX
@article{Buneeva2025,
  author = {Buneeva, O A and Kapitsa, I G and Zavyalova, M G and Kaloshina, S A and Zgoda, V G and Medvedev, A E},
  title = {The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism},
  journal = {Biomeditsinskaya Khimiya},
  year = {2025},
  doi = {10.18097/pbmcr1586}
}
Kostenlos starten →